No Data
No Data
No Data
Major authorization landed! International ophthalmology innovative drug company Pocan Vision Cloud sprints for Hong Kong stocks.
In recent years, the incidence of international ophthalmic diseases has significantly increased, while the diagnosis rate has been relatively lagging. With the enhancement of public health awareness, a large number of patients’ needs urgently need to be met. Although the market opportunity is large, the technical threshold in the field of ophthalmic drugs is high.
IPO News | HKEx lost US$129 million in 2023
As disclosed by the Hong Kong Stock Exchange on May 31, CLOUDBREAK PHARMA INC. (Baokang Shiyun) Submitted a listing application to the main board of the Hong Kong Stock Exchange for the second time. UBS UBS Group, CCB International, and Huatai International were co-sponsors.
New Survey Results From Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease
Bokang Shiyun's sprint to the Hong Kong Stock Exchange: Multiple drug candidates may become the first of its kind and the best treatment in its class
According to news from the IPO, CLOUDBREAK PHARMA INC. (hereinafter referred to as “Diakang Shiyun”) officially submitted a prospectus to the Hong Kong Stock Exchange on November 30, 2023, to be listed on the Main Board. UBS Group, CCB International, and Huatai International act as co-sponsors.
[IPO] Call Kang Shiyun to submit a listing application to the main board of the Hong Kong Stock Exchange
Jinwu Financial News | According to the disclosure of the Hong Kong Stock Exchange on November 30, Kang Shiyun submitted a listing application to the main board of the Hong Kong Stock Exchange. UBS, CCB International, and Huatai International are co-sponsors.
IPO News | Ophthalmology biotechnology company called Kang Shiyun to report that R&D expenditure in the first half of the year reached US$11.95 million on the Hong Kong Stock Exchange
Baokang Shiyun has established an extensive and innovative pipeline of seven drug candidates, covering major diseases of the front and back of the eye.
No Data
No Data